Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2353 - Can We Predict Subsequent Brain Metastasis in Patients with Metastatic Breast Cancer?


11 Sep 2017


Poster display session


Breast Cancer


Sherif Farouk El Zawawy


Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365


S.F. El Zawawy

Author affiliations

  • Clinical Oncology, University of Alexandria Faculty of Medicine, 21321 - Alexandria/EG


Abstract 2353


The one year over all survival of breast cancer patients with brain metastasis is only 20%–40%. Approximately, 80% of brain metastases occur after the diagnosis of other systemic metastatic lesions. Due to this dismal prognosis, prophylactic approaches as cranial irradiation, high-dose methotrexate, or lapatinib could be evaluated as preventative measures. However, these approaches are usually toxic and cannot be applied to all patients. This study is carried out to evaluate risk factors that have an impact on subsequent development of brain metastasis in metastatic breast cancer patients and thus, those patients can be candidates for prophylactic measures.


The medical files of 267 metastatic patients were retrospectively reviewed for demographic, clinico pathological, metastatic and treatment characteristics.


46 out of 267 patients developed brain metastasis with an incidence of 17.2%. Significant risks include age 50y (P = 0.031), 24.2% premenopausal patients compared to 11.4% for postmenopausal (P = 0.013), Her2/neu overexpression (48.5%) and triple negative (35.3%) compared to 11.3% patients with ER positive (P = 0.0001, 0.003), high grade compared to low grade tumors (35.6% vs 12.6% P = 0.005). Patients with N2, 3 had higher risk than N0, 1 (44% vs 13.8%) (P = 0.01), 30.9% patients with disease free duration (DFD) 2years (P = 0.019, 0.033). 3.6% patients with bone only metastasis developed brain metastasis compared to 20.6% patients with visceral only metastasis and 27.4% patients with bone and visceral metastasis (P = 0.036, 0.014). 32.3% patients with lung containing metastasis developed brain metastasis compared to 57.3% patients with lung and liver containing metastasis and 9.2% of patients with liver containing metastasis (P = 0.038, 0.022).


Young patients with lung metastases, Her2/neu overexpression or triple negative with disease free duration < 2years carried the highest risk for brain metastases. Such patients may be candidate for screening or prophylactic strategies.

Clinical trial identification

Legal entity responsible for the study

Ethics committee, Faculty of Medicine, Alexandria University.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.